Friday, September 18, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutidebipolar disorderpsychiatry

Acta Psychiatrica Scandinavica commentary questions semaglutide findings in bipolar disorder

The authors argue a differential effect seen with semaglutide in bipolar disorder calls for a differential mechanistic explanation.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 20:00 ETSource: Acta psychiatrica Scandinavica

The wire

  1. 01A commentary in Acta Psychiatrica Scandinavica addresses semaglutide in bipolar disorder, arguing that a differential finding requires a differential mechanism.
  2. 02Psychiatric prescribers are increasingly asked about GLP-1 use in patients on mood stabilizers, where metabolic burden and drug interactions both matter.
  3. 03This is commentary rather than new trial data, and the underlying clinical evidence base in bipolar disorder remains limited.

From the source

Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism

Acta psychiatrica Scandinavica · 2026 Sep 17 · Demas A et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42754946/